In Response
- PMID: 40742902
- DOI: 10.1213/ANE.0000000000007664
In Response
Conflict of interest statement
Conflicts of Interest: The original article was supported by a grant from Merck Sharp & Dohme Corp., the company that owns and markets sugammadex.
References
-
- Zhao D, Chen L, Wang H. Sugammadex and gastric emptying: individualized patient effects. Anesth Analg. 2025;141:e53–e54.
-
- Togioka BM, Rakshe SK, Ye S, et al. A randomized controlled trial of sugammadex versus neostigmine for reversal of rocuronium on gastric emptying in adults undergoing elective colorectal surgery. Anesth Analg. 2025;141:373–383.
-
- Franz MG, Smith PD, Wachtel TL, et al. Fascial incisions heal faster than skin: a new model of abdominal wall repair. Surgery. 2001;129:203–208.
-
- Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg. 2008;107:130–137.
-
- Ludwig K, Enker WE, Delaney CP, et al. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg. 2008;143:1098–1105.
LinkOut - more resources
Full Text Sources
